Compare Sana Biotechnology Inc (SANA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Standard Lithium Ltd — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Standard Lithium Ltd trades at $2.27 (market cap $523.89M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| SANA | SLI | |
|---|---|---|
Market Cap | $873.84M | $523.89M |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $5.65 |
52-Week Low | $2.68 | $2.15 |
Enterprise Value | $848.03M | $383.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting ongoing bearish technical momentum despite a 100% buy rating from 3 analysts. The stock shows negative profitability with ROE at -16.6% and net income of -$48.40M in 2025, though recent Q1 2026 earnings beat expectations. Key developments include progress on its Arkansas lithium project, a $225M DOE grant, and a binding offtake agreement with Trafigura, positioning the company for future production by 2029.
The investment case hinges on successful project execution and lithium market dynamics, offering high growth potential but carrying significant operational and funding risks. Current negative cash flows and reliance on financing highlight volatility, making it suitable for risk-tolerant investors betting on the energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
